Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot study.
Previous studies reported that both cilnidipine and azelnidipine have a renoprotective effect compared with amlodipine. The aim of this study was to compare the effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria. An open-label prospective crossover trial was carried out. We recruited 19 type 2 diabetics treated with amlodipine (5 mg/day) at least for 12 weeks. At study entry, amlodipine was changed to cilnidipine (10 mg/day) or azelnidipine (16 mg/day) and each administered for 16 weeks. Then, the drugs were switched and the treatment was continued for another 16 weeks. Despite no differences in 24-h blood pressure and heart rate between cilnidipine and azelnidipine, treatment with cilnidipine resulted in a greater reduction in urinary albumin:creatinine ratio than azelnidipine. Our results suggested that cilnidipine is more efficient in reducing albuminuria than azelnidipine independent of its blood pressure lowering effect in type 2 diabetic patients with hypertension. This trial was registered with UMIN (no. 000007201).
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan.
Hiroko
H
Abe
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan ; Center for Molecular Diabetology Juntendo University Graduate School of Medicine Tokyo Japan.
Tomoya
T
Mita
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan.
Risako
R
Yamamoto
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan.
Koji
K
Komiya
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan.
Minako
M
Kawaguchi
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan.
Yuko
Y
Sakurai
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan.
Tomoaki
T
Shimizu
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan.
Chie
C
Ohmura
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan.
Fuki
F
Ikeda
Sportology Center Juntendo University Graduate School of Medicine Tokyo Japan.
Ryuzo
R
Kawamori
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan ; Center for Beta Cell Biology and Regeneration Juntendo University Graduate School of Medicine Tokyo Japan.
Yoshio
Y
Fujitani
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan ; Center for Molecular Diabetology Juntendo University Graduate School of Medicine Tokyo Japan ; Sportology Center Juntendo University Graduate School of Medicine Tokyo Japan ; Center for Beta Cell Biology and Regeneration Juntendo University Graduate School of Medicine Tokyo Japan ; Center for Therapeutic Innovations in Diabetes Juntendo University Graduate School of Medicine Tokyo Japan.
Hirotaka
H
Watada
Albuminuria; Calcium channel blocker; Diabetes